Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 476 - 500 of 624 Clear search
Zyme Communications
Healthcare and Life Science 17 May 2022

Dotmatics supports Umicore Corporate R&D in processing of experimental data

Boston, MA, Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, announces it has been selected by Umicore Corporate Research and Development, which is part of global materials technology and recycling company Umicore, as informatics partner for its Corporate R&D (CRD) digitalization project.

Zyme Communications
Healthcare and Life Science 16 May 2022

AffyXell expands its strategic partnership with GenScript ProBio

London and Wetherby, UK: Avacta Group plc, a clinical stage oncology drug company developing innovative cancer therapies and powerful diagnostics based on its proprietary pre|CISION™ and Affimer® platforms, is pleased to announce that AffyXell, its joint venture with South Korean drug maker Daewoong Pharmaceutical, has expanded its strategic partnership with GenScript ProBio, a leading…

Zyme Communications
26 Apr 2022

Dotmatics, previously Insightful Science, set to transform the future of scientific software and data management

Boston, MA, — Dotmatics is announced as the formal name and brand for the combined entities of Insightful Science and Dotmatics. As the Insightful Science brand is retired, the new Dotmatics company is now inclusive of the Dotmatics’ enterprise scientific platform and many of scientists’ favorite applications including SnapGene, Geneious, and GraphPad Prism to offer end-to-end solutions for…

Zyme Communications
26 Apr 2022

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), introduces its PhysioMimix™ ‘in-a-box’ reagent kit for Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).

Zyme Communications
25 Apr 2022

Evonetix appoints Paul Beastall as Chair of Board of Directors

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announces the appointment of Paul Beastall as Chair of the Board of Directors.

Zyme Communications
21 Apr 2022

Codexis and seqWell announce strategic investment and partnership initiation

Redwood City, Calif. and Beverly, Mass., Codexis Inc. and seqWell Inc. announces the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions.

Zyme Communications
20 Apr 2022

Bio-Rad enhances multiplex flow cytometry with three new StarBright UltraViolet Dyes

The StarBright UltraViolet 510, StarBright UltraViolet 665, and StarBright UltraViolet 795 Dyes Offer Exceptional Brightness with Narrow Excitation and Emission Profiles to Support Multiplex Panels.

Zyme Communications
13 Apr 2022

Avacta announces AffyXell joint venture milestone and increased equity stake

Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics, a joint venture between Avacta and Daewoong Pharmaceutical in South Korea.

Zyme Communications
11 Apr 2022

Bio-Rad introduces anti-cemiplimab antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, introduces a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1). These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug…

Zyme Communications
08 Apr 2022

AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center

Cambridge and Wetherby: Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that AffyXell Therapeutics, a joint venture between Avacta and Daewoong Pharmaceutical, has entered into a collaboration agreement with Biocytogen, a Chinese company specializing in developing new…

Zyme Communications
08 Apr 2022

Axol Bioscience raises £3.2 million GBP

Cambridge, UK: Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, announces that it has raised £3.2 million GBP (circa $4.2 million USD) in the extension of its previous funding round, bringing the total raised to £7 million GBP (circa $9.2 million USD). The round was led by existing investors…

Zyme Communications
07 Apr 2022

Insightful Science bolsters executive team with senior sales and marketing expertise to accelerate growth Initiatives

San Diego, CA: Insightful Science, the global leader in R&D scientific software that connects science, data, and decision-making, today announced the appointments of Marta DeBellis as Chief Marketing Officer (CMO), and Stephanie Furfaro as Chief Revenue Officer (CRO). The appointments further strengthen the executive team as the Company continues to grow exponentially and scales the…

Zyme Communications
05 Apr 2022

Cell Guidance Systems and Manchester BIOGEL collaborate to launch PODS-PeptiGels for 3D cell culture

Cell Guidance Systems Ltd, a specialist in the control, manipulation, and monitoring of cells, both in vitro and in vivo, and Manchester BIOGEL, a biotechnology company specialising in the design and manufacture of 3D synthetic peptide hydrogels, announces a collaboration to launch PODS®-PeptiGels®.

Zyme Communications
04 Apr 2022

Evonetix granted patent for technology enabling thermally-controlled DNA synthesis

​EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, announces it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips.

Zyme Communications
04 Apr 2022

Arrayjet introduces Mercury range of next-generation microarray printers

Edinburgh, Scotland: Arrayjet, a leading provider of inkjet liquid-handling solutions, today introduced Mercury, a new core range of five instruments for ultra-low-volume liquid dispensing. The new print dispensers offer radically improved functionality and reliability, with further enhanced speed and precision.

Zyme Communications
04 Apr 2022

Fujifilm completes acquisition of Shenandoah Biotechnology

TOKYO: FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading…

Zyme Communications
22 Mar 2022

Fujifilm to acquire Shenandoah Biotechnology, leading manufacturer of recombinant proteins

The acquisition offers customers worldwide a single point of access for cGMP cell culture solutions for biopharmaceuticals, and cell and gene therapies.

Zyme Communications
22 Mar 2022

Closed Loop Medicine announces completion of Precision Medicine Clinical Trial for patients with high blood pressure

Cambridge and London:  Closed Loop Medicine Ltd, a leader in the development of single prescription drug plus digital therapy (DTx) combination products to enable precision dosing and care, announces that the last patient has completed participation in a clinical trial investigating the Company’s integrated precision care product solution for patients with hypertension.

Zyme Communications
21 Mar 2022

Avacta appoints Dr Christina Coughlin as Non-Executive Director

Cambridge and Wetherby: Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces the appointment of Christina Coughlin, M.D., Ph.D., as Non-executive Director to the Board with immediate effect.

Zyme Communications
17 Mar 2022

ELRIG UK establishes Scientific Advisory Board

York, UK: The European Laboratory Research & Innovation Group (ELRIG) UK announces the formation of its Scientific Advisory Board (SAB) with the appointment of senior drug discovery experts: Dr Chas Bountra OBE, Dr Richard Eglen, Steve Rees OBE, Dr Cathy Tralau-Stewart, and Dr Ian Waddell.

Zyme Communications
09 Mar 2022

Flow Eighteen38 receives €5 million EUR (c.$5.58 million USD) to expand production and biophysical capabilities

Porto, Portugal, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, today announced a €5 million EUR (c.$5.58 million USD) investment into its protein production and biophysical characterization capabilities and services from its parent company, FairJourney Biologics S.A. (FJB), leaders in the discovery…

Zyme Communications
07 Mar 2022

Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies

Oxford, United Kingdom, Orbit Discovery (Orbit), a ground-breaking peptide discovery company, announces the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.

Zyme Communications
02 Mar 2022

Gyros Protein Technologies introduces PurePep Sonata+ peptide synthesizer

Uppsala, Sweden: Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of PurePep® Sonata®+, a mid-pilot scale peptide synthesizer. The new system is an upgraded version of the Company’s previous model, Sonata® XT, known for its reliability and robustness, to further strengthen the…

Zyme Communications
02 Mar 2022

Evonetix demonstrates novel enzymatic DNA synthesis method

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry.

Zyme Communications
01 Mar 2022

Optibrium adds augmented intelligence for compound design to its StarDrop small molecule drug discovery software

Optibrium Ltd, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis.

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 18
  • Page 19
  • Current page 20
  • Page 21
  • Page 22
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS